Spruce Biosciences
Clinical trials sponsored by Spruce Biosciences, explained in plain language.
-
New drug aims to cut risky steroid use for rare hormone disorder
Disease control TerminatedThis study tested whether a drug called Tildacerfont could help adults with classic congenital adrenal hyperplasia (CAH) safely reduce their high daily steroid doses. One hundred participants were randomly assigned to receive either Tildacerfont or a placebo for 24 weeks, followe…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Trial tests new drug to help kids with rare hormone disorder
Disease control TerminatedThis study tested a drug called tildacerfont in children aged 2 to 17 with congenital adrenal hyperplasia (CAH), a rare genetic hormone disorder. The main goal was to see if the drug was safe and if it could help control the disease, potentially allowing for a reduction in the st…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Hormone-Targeting drug tested for common Women's health condition
Disease control TerminatedThis study tested whether a drug called tildacerfont could safely lower high adrenal hormone levels in women with Polycystic Ovary Syndrome (PCOS). About 27 women with PCOS and elevated adrenal hormones were given either the study drug or a placebo for several weeks. The main goa…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC